Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor

2021 ◽  
Author(s):  
Laurène Parrot ◽  
Catherine Dong ◽  
Franck Carbonnel ◽  
Antoine Meyer
Keyword(s):  
Systematic Review ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Meta Analysis ◽  
Necrosis Factor

scholarly journals Systematic Review with Meta-analysis of Prospective Studies: Anti-tumour Necrosis Factor for Prevention of Postoperative Crohn’s Disease Recurrence

2015 ◽  
Vol 9 (10) ◽  
pp. 918-927 ◽  
Author(s):  
Yun Qiu ◽  
Ren Mao ◽  
Bai-li Chen ◽  
Yao He ◽  
Zhi-rong Zeng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Prospective Studies ◽  
Tumour Necrosis ◽  
Meta Analysis ◽  
Disease Recurrence ◽  
Necrosis Factor

Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment

2016 ◽  
Vol 18 (7) ◽  
pp. 667-675 ◽  
Author(s):  
E. J. de Groof ◽  
S. Sahami ◽  
C. Lucas ◽  
C. Y. Ponsioen ◽  
W. A. Bemelman ◽  
...  
Keyword(s):  
Systematic Review ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Meta Analysis ◽  
Perianal Fistula ◽  
Seton Drainage ◽  
Necrosis Factor

Systematic review: efficacy of escalated maintenance anti‐tumour necrosis factor therapy in Crohn's disease

2021 ◽  
Author(s):  
Vandita Y. Mattoo ◽  
Chamara Basnayake ◽  
William R. Connell ◽  
Nik Ding ◽  
Michael A. Kamm ◽  
...  
Keyword(s):  
Systematic Review ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Factor Therapy ◽  
Necrosis Factor

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

2011 ◽  
Vol 70 (11) ◽  
pp. 1895-1904 ◽  
Author(s):  
X. Mariette ◽  
M. Matucci-Cerinic ◽  
K. Pavelka ◽  
P. Taylor ◽  
R. van Vollenhoven ◽  
...  
Keyword(s):  
Systematic Review ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Observational Studies ◽  
Meta Analysis ◽  
Tumour Necrosis Factor Inhibitors ◽  
Necrosis Factor

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease

The Lancet ◽  
1997 ◽  
Vol 349 (9051) ◽  
pp. 521-524 ◽  
Author(s):  
WA Stack ◽  
SD Mann ◽  
AJ Roy ◽  
P Heath ◽  
M Sopwith ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Randomised Controlled Trial ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Controlled Trial ◽  
Tumour Necrosis Factor Α ◽  
Randomised Controlled ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn’s Disease

2019 ◽  
Vol 13 (7) ◽  
pp. 905-915 ◽  
Author(s):  
Shrinivas Bishu ◽  
Mohammed El Zaatari ◽  
Atsushi Hayashi ◽  
Guoqing Hou ◽  
Nicole Bowers ◽  
...  
Keyword(s):  
T Cells ◽  
Crohn’S Disease ◽  
T Cell ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Ex Vivo ◽  
Factor Α ◽  
And Control ◽  
Necrosis Factor

Abstract Background and Aims Tumour necrosis factor [TNF]α- and IL-17A-producing T cells are implicated in Crohn’s disease [CD]. Tissue-resident memory T [TRM] cells are tissue-restricted T cells that are regulated by PR zinc finger domain 1 [PRDM1], which has been implicated in pathogenic Th17 cell responses. TRM cells provide host defence but their role in CD is unknown. We thus examined CD4+ TRM cells in CD. Methods Colon samples were prospectively collected at endoscopy or surgery in CD and control subjects. Flow cytometry and ex vivo assays were performed to characterise CD4+ TRM cells. Results CD4+ TRM cells are the most abundant memory T cell population and are the major T cell source of mucosal TNFα in CD. CD4+ TRM cells are expanded in CD and more avidly produce IL-17A and TNFα relative to control cells. There was a unique population of TNFα+IL-17A+ CD4+ TRM cells in CD which are largely absent in controls. PRDM1 was highly expressed by CD4+ TRM cells but not by other effector T cells. Suppression of PRDM1 was associated with impaired induction of IL17A and TNFA by CD4+ TRM cells Conclusions CD4+ TRM cells are expanded in CD and are a major source of TNFα, suggesting that they are important in CD. PRDM1 is expressed by TRM cells and may regulate their function. Collectively, this argues for prospective studies tracking CD4+ TRM cells over the disease course.

scholarly journals Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody

2020 ◽  
Author(s):  
Judith Pichler ◽  
Nima Memaran ◽  
Wolf Dietrich Huber ◽  
Christoph Aufricht ◽  
Bettina Bidmon‐Fliegenschnee
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document